Evidence map›Paper›PMID 38707823›Full record

ArticleKidney international reports2024

Renal Disease in Metabolic Syndrome: the Hidden Role of Intrarenal Ischemia.

Rosa Rodríguez-Rodríguez, Mads Hornum, Ana Elena Rodríguez Rodríguez, Sebastjan Bevc, Francesco Trevisani, Gema Fernández, Radovan Hojs, Beatriz Fernández-Fernández, Clara María Cases Corona, Josep María Cruzado and 18 more

Erratum issuedAbstract read
In one paragraph

Article in Kidney international reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors.

Rosa Rodríguez-RodríguezHospital Universitario de Canarias, Pathology Department. Tenerife, Spain.
Mads HornumRigshospitalet, Copenhagen, Denmark.
Ana Elena Rodríguez RodríguezResearch Unit, Hospital Universitario de Canarias, Tenerife, Spain.
Sebastjan BevcDepartment of Nephrology, Clinic for Internal Medicine, University Clinical Centre Maribor and Faculty of Medicine, University of Maribor, Slovenia.
Francesco TrevisaniIRCCS Ospedale San Raffaele, URI-Urological Research Institute, Milano, Italy.
Gema FernándezHospital La Paz, Nephrology Department. Madrid, Spain.
Radovan HojsDepartment of Nephrology, Clinic for Internal Medicine, University Clinical Centre Maribor and Faculty of Medicine, University of Maribor, Slovenia.
Beatriz Fernández-FernándezIIS-Fundación Jiménez Díaz-UAM, Madrid, Spain.
Clara María Cases CoronaHospital Universitario Fundación Alcorcón, Madrid, Spain.
Josep María CruzadoNephrology Department. Hospital Universitario de Bellvitge. Biomedical Research Institute (IDIBELL). Departamento de Ciencias Clínicas, Facultad de Medicina, Universidad de Barcelona. Hospitalet de Llobregat, Spain.
María QueroNephrology Department. Hospital Universitario de Bellvitge. Biomedical Research Institute (IDIBELL). Departamento de Ciencias Clínicas, Facultad de Medicina, Universidad de Barcelona. Hospitalet de Llobregat, Spain.
Maruja Navarro DíazHospital Moisés Broggi, Nephrology Department. Barcelona, Spain.
Arianna BettigaIRCCS Ospedale San Raffaele, URI-Urological Research Institute, Milano, Italy.
Francisco MoresoHospital Universitario Vall d'Hebron, Barcelona, Spain.
Clara García CarroHospital Universitario Clínico San Carlos, Nephrology Department, Madrid, Spain.
Khaled KhazimGalilee Medical Center, Nahariya, Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
Fedaa GhanemGalilee Medical Center, Nahariya, Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
Meritxell IbernónHospital Moisés Broggi, Nephrology Department. Barcelona, Spain.
Ivo LaranjinhiaHospital de Santa Cruz Lisboa, Lisboa, Portugal.
Luís MendonçaCentro Hospitalar Lisboa Norte, Lisboa, Portugal.
Miguel Bigotte VieiraCentro Hospitalar São João, Porto, Portugal.
Bo Feldt-RasmussenRigshospitalet, Copenhagen, Denmark.
Alberto OrtizIIS-Fundación Jiménez Díaz-UAM, Madrid, Spain.
Per BagiDepartment of Urology, Faculty of Health and Medical Sciences, University of Copenhagen, Rigshospitalet, Denmark.
Cristian Acosta SorensenResearch Unit, Hospital Universitario de Canarias, Tenerife, Spain.
Enrique MoralesHospital 12 de Octubre, Madrid, Spain.
Esteban PorriniFaculty of Medicine, University of La Laguna, Tenerife, Spain.
DIABESITY working group of the European Renal Association

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The pathogenesis of renal disease in obesity and metabolic syndrome (MS) is mostly unknown. This is in part because of the limited information about renal morphological changes in these conditions. We evaluated renal histology in subjects with MS and those without MS, who are participants in the European Nephrectomy Biobank (ENBiBA) project. Methods: MS was defined with at least 3 of the following criteria: (i) body mass index (BMI) ≥27 kg/m Results: A total of 157 cases were evaluated: 49 without and 108 with MS. Those with MS were older (54 ± 16 vs. 66 ± 11, Conclusion: In MS, ischemic renal disease may play a role in renal disease. In addition, some patients may develop lesions compatible with diabetic nephropathy such as increased mesangial expansion and nodular sclerosis. Further analyses are needed to study the consequences of the pandemic of obesity on renal health.

Indexed as

diabetic nephropathymetabolic syndromevascular disease

Identifiers

PMID38707823
PMCPMC11068944

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.